Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P53 REAL-WORLD TREATMENT SEQUE...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P53 REAL-WORLD TREATMENT SEQUENCES AND COSTS OF 96 PATIENTS WITH MULTIPLE MYELOMA FROM DIAGNOSIS TO DEATH

P53 REAL-WORLD TREATMENT SEQUENCES AND COSTS OF 96 PATIENTS WITH MULTIPLE MYELOMA FROM DIAGNOSIS TO DEATH

Bibliographic Details
Main Authors: M.R. Seefat, D.G.J. Cucchi, K. Groen, M.L. Donker, K.G. van der Hem, M. Westerman, A.M. Gerrits, A. Beeker, N. van de Donk, H.M. Blommestein, S. Zweegman
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000936340.30450.37
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000936340.30450.37

Similar Items

  • P18 SKIN EXPRESSION OF P16INK4A, A BIOMARKER FOR CELLULAR SENESCENCE, DOES NOT PREDICT FRAILTY OR TREATMENT OUTCOME IN NEWLY DIAGNOSED MULTIPLE MYELOMA
    by: F. Smits, et al.
    Published: (2023-05-01)
  • Carfilzomib for relapsed and refractory multiple myeloma
    by: Groen K, et al.
    Published: (2019-04-01)
  • P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV)
    by: M.R. Seefat, et al.
    Published: (2023-05-01)
  • Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
    by: Christie P. M. Verkleij, et al.
    Published: (2021-03-01)
  • Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
    by: Kazimierz Groen, et al.
    Published: (2024-07-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs